Barclays raised the firm’s price target on Agilon Health (AGL) to $3 from $2 and keeps an Underweight rating on the shares. Despite a Q1 headline beat, the company’s “soft” Q2 guidance and lingering uncertainty on Part D / Group Medicare Advantage risk in the market are “reasons for continued caution,” the analyst tells investors in a research note.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGL:
- Agilon Health Inc’s Mixed Q1 Earnings Call Review
- Cautious Hold Rating on Agilon Health Amid Uncertainties Despite Strong Q1 FY25 Performance
- Cautious Outlook on Agilon Health: Financial Challenges and Strategic Concerns Drive Sell Rating
- Agilon Health Reports Q1 2025 Financial Results
- Agilon Health: Hold Rating Amid Positive Results and Cost Concerns